SCHEMBL5136262

SCHEMBL5136262

CCCCC(c1cnc(-c2ccccc2)n1CCCC)N(Cc1ccccc1)Cc1cccc(C(=O)OC)c1

nearest known ligand 0.41

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 16/20 0.41
NR3C1 P04150 1/20 0.39
UBE2M P61081 1/20 0.39
DCUN1D1 Q96GG9 1/20 0.39
CMA1 P23946 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135309 0.95 TLR7 (0.41) TLR7
SCHEMBL5134955 0.91 LTB4R2 (0.41)
SCHEMBL5136929 0.88 LTB4R2 (0.37)
SCHEMBL650145 0.87 LPAR1 (0.40)
SCHEMBL5137583 0.85 HSP90AA1 (0.39) TLR7
SCHEMBL5134818 0.85 TSHR (0.39) TLR7
SCHEMBL5137355 0.85 TSHR (0.39) TLR7CMA1
SCHEMBL5135943 0.85 C5AR1 (0.36)
SCHEMBL5134753 0.82 STAT3 (0.40)
SCHEMBL5134552 0.82 TSHR (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed